Filing Details
- Accession Number:
- 0001209191-11-021302
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-04-04 20:25:54
- Reporting Period:
- 2011-03-31
- Filing Date:
- 2011-04-04
- Accepted Time:
- 2011-04-04 20:25:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1360376 | Juergen Lasowski | C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080 | Evp, Corporate Development | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-03-31 | 5,500 | $0.00 | 20,593 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2011-03-31 | 22,500 | $0.00 | 43,093 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2011-04-01 | 1,478 | $35.02 | 41,615 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2011-03-31 | 38,500 | $0.00 | 38,500 | $35.18 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2011-03-31 | 40,000 | $0.00 | 40,000 | $35.18 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 38,500 | 2021-03-31 | No | 4 | A | Direct | |
| 40,000 | 2021-03-31 | No | 4 | A | Direct |
Footnotes
- Represents a restricted stock awarded to the reporting person. One-third of the award vests annually over three years.
- Includes shares purchased through the issuer's ESPP.
- Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock unit vests upon the meeting of certain milestones.
- Shares sold pursuant to a 10b5-1 plan.
- 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
- The shares vest monthly from the date of grant at a rate of 1/48th per month over a period of 48 months.
Billionaire Hedge Funds
